MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Up 0.5% – Should You Buy?

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA)’s stock price traded up 0.5% during mid-day trading on Monday . The company traded as high as $1.98 and last traded at $1.98. 582,924 shares were traded during mid-day trading, a decline of 54% from the average session volume of 1,270,098 shares. The stock had previously closed at $1.97.

MAIA Biotechnology Price Performance

The firm’s 50-day simple moving average is $1.70 and its 200 day simple moving average is $1.53. The firm has a market capitalization of $73.32 million, a price-to-earnings ratio of -2.71 and a beta of -0.07.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its quarterly earnings results on Friday, November 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.08). As a group, research analysts predict that MAIA Biotechnology, Inc. will post -1.3 earnings per share for the current year.

Insiders Place Their Bets

In other MAIA Biotechnology news, Director Ngar Yee Louie bought 81,699 shares of the firm’s stock in a transaction on Monday, December 22nd. The shares were purchased at an average price of $1.22 per share, for a total transaction of $99,672.78. Following the completion of the transaction, the director directly owned 1,248,888 shares in the company, valued at approximately $1,523,643.36. The trade was a 7.00% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Steven M. Chaouki bought 40,849 shares of the stock in a transaction on Monday, December 22nd. The shares were acquired at an average cost of $1.22 per share, with a total value of $49,835.78. Following the purchase, the director owned 151,873 shares of the company’s stock, valued at approximately $185,285.06. This represents a 36.79% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have bought 349,122 shares of company stock worth $402,193. Insiders own 32.32% of the company’s stock.

Institutional Trading of MAIA Biotechnology

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Centerpoint Advisory Group acquired a new position in shares of MAIA Biotechnology in the second quarter valued at approximately $28,000. Geode Capital Management LLC boosted its position in MAIA Biotechnology by 3.6% during the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after buying an additional 7,746 shares during the period. Centric Wealth Management grew its holdings in MAIA Biotechnology by 740.2% during the 2nd quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock worth $1,032,000 after acquiring an additional 505,150 shares during the last quarter. Marshall Wace LLP acquired a new position in MAIA Biotechnology in the 2nd quarter valued at approximately $29,000. Finally, Jane Street Group LLC bought a new position in shares of MAIA Biotechnology during the second quarter valued at $52,000. 5.65% of the stock is currently owned by institutional investors.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.